Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash from Operations (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Cash from Operations for 5 consecutive years, with 77508000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 46.68% to 77508000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 200865000.0 through Dec 2025, up 62.75% year-over-year, with the annual reading at 200865000.0 for FY2025, 62.75% up from the prior year.
  • Cash from Operations hit 77508000.0 in Q4 2025 for Krystal Biotech, up from 39659000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 77508000.0 in Q4 2025 to a low of 43059000.0 in Q2 2022.
  • Historically, Cash from Operations has averaged 4348700.0 across 5 years, with a median of 8454500.0 in 2021.
  • Biggest five-year swings in Cash from Operations: crashed 325.11% in 2022 and later skyrocketed 1365.09% in 2025.
  • Year by year, Cash from Operations stood at 20900000.0 in 2021, then decreased by 6.84% to 22329000.0 in 2022, then skyrocketed by 67.61% to 7232000.0 in 2023, then skyrocketed by 830.68% to 52843000.0 in 2024, then surged by 46.68% to 77508000.0 in 2025.
  • Business Quant data shows Cash from Operations for KRYS at 77508000.0 in Q4 2025, 39659000.0 in Q3 2025, and 52729000.0 in Q2 2025.